Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Summit Therapeutics (SMMT) Shares Outstanding (2019 - 2026)

Summit Therapeutics filings provide 8 years of Shares Outstanding readings, the most recent being $776.0 million for Q1 2026.

  • Quarterly Shares Outstanding rose 4.64% to $776.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $776.0 million through Mar 2026, up 4.64% year-over-year, with the annual reading at $775.4 million for FY2025, 5.12% up from the prior year.
  • Shares Outstanding hit $776.0 million in Q1 2026 for Summit Therapeutics, roughly flat from $775.4 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $776.0 million in Q1 2026 and bottomed at $98.1 million in Q1 2022.
  • Average Shares Outstanding over 5 years is $593.2 million, with a median of $702.0 million recorded in 2024.
  • The largest annual shift saw Shares Outstanding skyrocketed 611.04% in 2023 before it grew 0.61% in 2024.
  • Summit Therapeutics' Shares Outstanding stood at $211.1 million in 2022, then skyrocketed by 232.4% to $701.7 million in 2023, then grew by 5.13% to $737.6 million in 2024, then increased by 5.12% to $775.4 million in 2025, then increased by 0.08% to $776.0 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Shares Outstanding are $776.0 million (Q1 2026), $775.4 million (Q4 2025), and $744.4 million (Q3 2025).